Lipocine (NASDAQ:LPCN – Get Free Report) issued its quarterly earnings results on Thursday. The specialty pharmaceutical company reported $0.33 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.59, Zacks reports.
Lipocine Stock Up 3.5 %
Shares of Lipocine stock opened at $3.21 on Thursday. Lipocine has a 52 week low of $2.91 and a 52 week high of $11.79. The business has a 50 day moving average price of $4.01 and a 200-day moving average price of $4.53. The company has a market cap of $17.17 million, a PE ratio of -4.22 and a beta of 1.42.
Analysts Set New Price Targets
Separately, StockNews.com began coverage on Lipocine in a report on Thursday, March 6th. They set a “hold” rating on the stock.
About Lipocine
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Featured Stories
- Five stocks we like better than Lipocine
- ESG Stocks, What Investors Should Know
- Is a Bottom Finally Forming in Rocket Lab Stock?
- Following Congress Stock Trades
- Gold Rally vs. Oil Surge: Where Investors Are Betting Next
- The Basics of Support and Resistance
- Intel Stock Surges on New CEO – The Real Story Runs Deeper
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
